Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BALANCE-II
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Oct 2019 Results of exposure response analysis of upadacitinib using data from Phase 2 and Phase 3 rheumatoid arthritis (RA) studies published in the Clinical Pharmacology and Therapeutics
    • 15 Jun 2019 Results evaluating the effect of Upadacitinib treatment on cholesterol efflux capacity (CEC) from a subset of patients from the Phase 2 BALANCE II study 2 and the Phase 3 SELECT-NEXT study, are presented at the 20th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2019 Results of exposue response analysis of Upadacitinib efficacy in phase 2 trials (BALANCE-I and BALANCE-II) published in the Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top